A Phase 2 interventional study of Placebo and EPI-743 15 mg/kg in Leigh Syndrome, sponsored by PTC Therapeutics. Completed at 4 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-31.
Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.
Among the 14 studies in Leigh Disease with a site in United States, this one is one of 3 that started in 2012, is one of 5 in phase 2, and was the 4th registered.
20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.
Browse Leigh Disease studies →6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 days–100 yrs
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 4 wk–115 yrs · Healthy volunteers
Columbia University · Sites in United States, Canada
Healthy volunteers
Sanford Health · Sites in United States
Matthew Demczko · Sites in United States
Ages 6 mo–55 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 2
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is above the median of 31 across 10 interventional studies indexed under Leigh Disease.
Median enrollment 35 across the 7 interventional studies, 750 across the 6 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 8 most frequent:
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
PTC Therapeutics has 5 studies filed under Leigh Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Leigh Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Leigh Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.
The purpose of this study is to evaluate the effects of EPI-743 in patient with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and biomarkers associated with the disease.
This study is a six month prospective randomized double-blind, placebo-controlled trial with a six month extension phase of two dose levels of EPI743. The planned enrollment is for approximately 30 children with genetically confirmed Leigh syndrome. After 6 months of treatment, those children that were randomized to the placebo treatment arm will be re-randomized to one of the 2 active treatment arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient will receive a volume of placebo based on weight
Drug: Placebo
Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
Drug: EPI-743 15 mg/kg
Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
Drug: EPI-743 5 mg/kg
Drug page: Alpha-tocotrienol quinone
Drug page: Alpha-tocotrienol quinone
Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3
Change from baseline to six months will be compared between subjects in active treatment group and placebo group
Time frame: 6 months
Neuromuscular function
Gross Motor Function Measure; Barry Albright Dystonia Scale
Time frame: 6 months
Respiratory function
Need for tracheostomy
Time frame: 6 months
Disease morbidity
Total number of hospitalizations
Time frame: 6 months
Glutathione cycle biomarkers
Blood levels of glutathione will be compared between placebo and treatment group
Time frame: 6 months
Number of dose limiting serious adverse events
Time frame: 6 months
Mortality
Number of deaths
Time frame: 6 months
Plan to share: Undecided
Ran from Oct 2012 to primary completion in Feb 2015, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone